Clinical trial · Interventional
Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer
NCT02701231CI-TRIAL-00021274unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether Low-frequency Rotating Magnetic Therapy System is effective and safe in the treatment of advanced lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low-frequency Rotating Magnetic Therapy System | Device | — | UNRESOLVED |
| Sham Low-frequency Rotating Magnetic Therapy System | Device | — | UNRESOLVED |
| Systemic anti-tumor therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- SHAM_COMPARATOR
- label
- Sham control
- description
- Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
- interventionNames
- Drug: Systemic anti-tumor therapy
- Device: Sham Low-frequency Rotating Magnetic Therapy System
- type
- EXPERIMENTAL
- label
- Low-frequency Rotating Magnetic Therapy
- description
- Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
- interventionNames
- Device: Low-frequency Rotating Magnetic Therapy System
- Drug: Systemic anti-tumor therapy
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Willing and able to give written informed consent * Male or female aged 18 years and older * Histologic diagnosis of non-small cell lung cancer (unable to receive surgery) or small cell lung cancer (limited stage or extensive stage) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3- going to receive systemic anti-tumor therapy * Measurable disease based on RECIST 1.1 * Adequate hematologic and organ function Exclusion Criteria: * Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device * Unable to lie in bed * With any metal implants in body * Human immunodeficiency virus (HIV) * Malignancies other than lung cancer within 5 years prior to randomization * History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the trial or interfere with the subject's participation for the full duration of the trial * Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
References
Publications (1)
- DERIVEDZhu M, Yang Z, Yu H, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Liang Z, Chen L. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial. Int J Radiat Biol. 2020 Jul;96(7):943-950. doi: 10.1080/09553002.2020.1748737. Epub 2020 Apr 13. PMID 32238091